Mellozzan[® ](melatonin) have gained marketing approval in the UK
EQL's key product Mellozzan[®] has now gained marketing approval by the Health Authorities in the UK, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Pütter GmbH & Co. KG. Launch of Mellozzan in the UK is planned for the financial year 2024/25, subject to reimbursement approvals and manufacturing capabilities. In addition to the UK the licensee also has ongoing work for registrations and subsequent launches in Finland and Switzerland. In 2023, Medice launched Mellozzan[®] in Denmark and Norway and launch preparations are nearing completion in Germany and